Literature DB >> 64292

The role of IgE in the immune response to neoplasia: a review.

J T Rosenbaum, J M Dwyer.   

Abstract

The role of IgE in the immune response to neoplasia has received little attention despite suggestive evidence for an IgE response to tumor specific antigens. A complex interrelationship is known to exist between basophils, eosinophils, histamine, complement, and T cells. The latter cells are known to play a central role in the immune response to neoplasia and, in addition, are now considered important in the production and regulation of IgE, the molecule that may supply an important link between pharmacological and cellular dynamics of a successful anti-tumor response. The evidence for an IgE role in the immune response to tumors, the relationship between atopy and cancer, and the possible mechanisms whereby IgE could enhance tumor rejection are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 64292     DOI: 10.1002/1097-0142(197701)39:1<11::aid-cncr2820390104>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Omalizumab: a monoclonal anti-IgE antibody.

Authors:  Paul P Belliveau
Journal:  MedGenMed       Date:  2005-01-27

Review 2.  Basophils in human disease.

Authors:  E B Mitchell; P W Askenase
Journal:  Clin Rev Allergy       Date:  1983-09

3.  Tumor-reactive IgE antibodies in plasma of patients with gastrointestinal carcinomas.

Authors:  I Berczi; V Holford-Strevens; Z H Warsi; L S McMorris; R H Thorlakson; T K Thorlakson; A H Sehon
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Prognostic significance of serum IgE levels in primary breast cancer.

Authors:  D R Ownby; H E Ownby; L D Roi; L M Howard; G H Heppner; M J Brennan
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

5.  Testicular cancer and antecedent diseases.

Authors:  A J Swerdlow; S R Huttly; P G Smith
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.